11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one dihydrochloride
• 英文别名: hydron;11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;dichloride
• 化学式: C19H23Cl2N5O2
• 分子量: 424.3
• InChiKey: FFNMBRCFFADNAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  68.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-二氯-1,4-萘醌 、 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one dihydrochloride 生成 Naphth<2',3':4,5>imidazo<1,2-a>pyridin-6,11-dion
  参考文献：
  名称：

  Antiviral Compounds and Methods of Use Thereof

  摘要：

  本文披露了逆转录病毒传播的抑制剂、使用这些抑制剂进行逆转录病毒感染的治疗和预防方法，以及包括这些抑制剂的制药组合物。

  公开号：

  US20130071353A1
• 作为产物：
  描述：

  5,11-二氢-11-氯乙酰基-6H-吡啶并[2.3-b][1,4]苯并二氮卓-6-酮 、 N-甲基哌嗪 、 盐酸 以74%的产率得到
  参考文献：
  名称：

  FENG, JUNCAI;WU, MEIFANG;ZHANG, LIN;SHA, JIAN;CHEN, WEIXING, PHARM. IND., 1984, N 2, 12-14

  摘要：

  DOI：

文献信息

• [EN] 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION<br/>[FR] OXINDOLES 3-3-DI-SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE L'INITIATION DE LA TRADUCTION
  申请人：HARVARD COLLEGE

  公开号：WO2005080335A1

  公开（公告）日：2005-09-01

  Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy­phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.

  提供了用于抑制翻译的组合物和方法，使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物。描述了使用3-(5-叔丁基-2-羟基苯基)-3-苯基-1,3-二氢吲哚-2-酮及/或其衍生物治疗(1)细胞增殖性疾病，(2)非增殖性、退行性疾病，(3)病毒感染和/或(4)与病毒感染相关的疾病的组合物、方法和试剂盒。
• Piperidine derivative and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20060142337A1

  公开（公告）日：2006-06-29

  The present invention provides a compound represented by the formula: wherein Ar is an aryl group optionally having substituents, R is a C 1-6 alkyl group, R 1 is a hydrogen atom, a hydrocarbon group optionally having substituents, an acyl group or a heterocyclic group optionally having substituents, X is an oxygen atom or an imino group optionally having substituents, ring A is a piperidine ring optionally further having substituents, and ring B is a benzene ring having substituents, or a salt thereof, and an agent for the prophylaxis or treatment of lower urinary tract abnormality and the like, which contains the compound.

  本发明提供了一种由以下公式表示的化合物： 其中Ar是一个芳基基团，可选地具有取代基，R是一个C1-6烷基基团，R1是一个氢原子，一个可选地具有取代基的烃基团，酰基团或杂环基团，X是一个氧原子或一个可选地具有取代基的亚胺基团，环A是一个哌啶环，可选地进一步具有取代基，环B是一个苯环，具有取代基，或其盐，以及含有该化合物的预防或治疗下尿道异常等的药剂。
• Piperidine derivative crystal, process for producing the same, and use
  申请人：Ikeura Yoshinori

  公开号：US20060241145A1

  公开（公告）日：2006-10-26

  The present invention provides a piperidine derivative having antagonistic action for tachykinin receptors and the like, a crystal thereof, and an agent for the prophylaxis or treatment of diseases including lower urinary tract disease and the like, which contains the derivative. Specifically, the present invention provides an optically active compound represented by the formula (I): wherein each symbol is as defined in the specification, and a salt thereof.

  本发明提供了一种对缓激肽受体等具有拮抗作用的哌啶衍生物，其晶体以及包含该衍生物的用于预防或治疗包括下尿路疾病等疾病的药剂。具体地，本发明提供了由下式（I）表示的光学活性化合物： 其中每个符号如规范中定义的那样，以及其盐。
• Benzofuran derivatives
  申请人：Tsukamoto Tetsuya

  公开号：US20100234357A1

  公开（公告）日：2010-09-16

  The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted homopiperazine ring; R 1 and R 2 are the same or different from each other, and represent a hydrogen atom or optionally substituted lower alkyl; R 3 and R 4 are the same or different from each other, and represent a hydrogen atom or halogenated or non-halogenated lower alkyl; R 5 to R 7 are the same or different from each other, and represent a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted aromatic heterocyclic ring, optionally substituted amino, or acyl; and represents a single bond or double bond, or a salt thereof.

  本发明提供了一种由以下式（I）表示的化合物： 其中： 环A代表可选择地取代的哌嗪环、可选择地取代的吗啉环或可选择地取代的同环丙二胺环； R1和R2彼此相同或不同，代表氢原子或可选择地取代的较低烷基； R3和R4彼此相同或不同，代表氢原子或卤代或非卤代的较低烷基； R5到R7彼此相同或不同，代表氢原子、羟基、可选择地取代的较低烷基、可选择地取代的较低烯基、可选择地取代的较低烷氧基、可选择地取代的环烷基、可选择地取代的芳基、可选择地取代的芳香杂环、可选择地取代的氨基或酰基；和 代表单键或双键，或其盐。
• [EN] MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES<br/>[FR] COMPOSÉS DE CIBLAGE MITOCHONDRIAL POUR LE TRAITEMENT DE MALADIES ASSOCIÉES
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021242753A1

  公开（公告）日：2021-12-02

  Mitochondrial targeting compounds for the treatment of cancer and other disorders associated with mitochondrial function, including diabetes, autoimmune diseases, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases and their preparation. The present invention is also directed to the pharmaceutical compositions and treatment methods, prodrugs based on those compounds and the use thereof.

  针对线粒体功能的癌症和其他疾病的治疗线粒体靶向化合物，包括糖尿病，自身免疫疾病，炎症性疾病，心血管疾病和神经退行性疾病及其制备方法。本发明还涉及基于这些化合物的药物组合物、治疗方法、前药及其用途。